Vanguard Global Advisers’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$46.2K Sell
5,582
-3
-0.1% -$35 ﹤0.01% 3094
2026
Q2
$75.1K Hold
5,585
– – ﹤0.01% 2911
2026
Q1
$74.7K Buy
+5,585
New +$78.5K ﹤0.01% 2849

Other funds holding RNA

Vanguard Global Advisers's RNA Position: Q3 2026 in Review

Vanguard Global Advisers reduced its Atrium Therapeutics (RNA) stake by 0.05% in Q3 2026, selling an estimated $35 and leaving 5,582 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3094.

Vanguard Global Advisers first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $75.1K in Q2 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Vanguard Global Advisers held 5,582 shares of Atrium Therapeutics worth $46.2K as of Q3 2026.
  • Vanguard Global Advisers sold 3 Atrium Therapeutics shares in Q3 2026, an estimated $35.
  • Atrium Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3094 holding.
  • Vanguard Global Advisers first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Atrium Therapeutics position peaked at $75.1K in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.